The purpose of the study is to assess how Pravastatin affects insulin sensitivity compared to a placebo. Participants in the study will receive either Pravastatin or a placebo. The study will involve taking the medication in the form of tablets over a period of time. The effects on insulin sensitivity will be monitored using a method called the hyperinsulinemic euglycemic glucose clamp, which is a way to measure how well the body responds to insulin.

In addition to Pravastatin, the study will also involve the use of other substances such as glucose, potassium chloride, and insulin (human), which will be administered intravenously. These substances are used to help understand the body’s response to insulin and to maintain necessary body functions during the study. The trial aims to provide insights into how Pravastatin might help improve insulin sensitivity in people with kidney-related health issues.